GSK plc Files 6-K on Share Transactions
Ticker: GLAXF · Form: 6-K · Filed: Sep 18, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transactions, 6-K, foreign-private-issuer
Related Tickers: GSK
TL;DR
GSK plc filed a 6-K for Sept 2025 detailing share transactions.
AI Summary
GSK plc filed a Form 6-K on September 18, 2025, reporting transactions in its own shares during the month of September 2025. The filing is a report of a foreign private issuer and indicates that GSK plc files annual reports under Form 20-F.
Why It Matters
This filing provides transparency on GSK's activities related to its own stock, which can be relevant for investors monitoring share buybacks or issuances.
Risk Assessment
Risk Level: low — This is a routine filing reporting on share transactions, not indicating any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- 001-15170 (company) — SEC File Number
- 79 New Oxford Street, London, WC1A 1DG (company) — Principal executive office address
- September 2025 (date) — Reporting period for share transactions
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the reporting period for this Form 6-K?
The report covers transactions for the month of September 2025.
What is the principal executive office address of GSK plc?
The principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F?
Yes, the filing indicates that the registrant files annual reports under cover of Form 20-F.
What is the subject of this Form 6-K filing?
The filing reports on 'Transaction in own shares'.
Filing Stats: 2,530 words · 10 min read · ~8 pages · Grade level 2.2 · Accepted 2025-09-18 07:17:47
Filing Documents
- a7761z.htm (6-K) — 3841KB
- 0001654954-25-010888.txt ( ) — 3842KB
From the Filing
IN OWN SHARES a7761z UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                       Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 17 September 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 209,886 Lowest price paid per share (GBp): 1,461.50p Highest price paid per share (GBp): 1,478.50p Volume-weighted average price paid per share (GBp): 1,471.87p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 29,314,603 ordinary shares.   Following the above purchase, the Company will hold 247,448,986 ordinary shares in treasury and have 4,067,953,982 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is 4,067,953,982. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.08 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases Shares purchased:      GSK plc (ISIN: GB00BN7SWP63) Date of purchases:      17 September 2025 Investment firm:         Merrill Lynch International     Aggregated information per trading venue:   Venue Number of ordinary shares purchased Highest price paid (per ordinary share) (GBp) Lowest price paid (per ordinary share) (GBp) Volume weighted average price paid (per ordinary share) (GBp) London Stock Exchange (XLON) 209,886 1,478.50p 1,461.50p 1,471.87p CBOE (CHIX) 0 - - - CBOE (BATE) 0 - - -     Individual transactions:   Number of Shares Price per Share (GBp) Trading venue Date of transaction Time of transaction Transaction reference number 3 1,461.50  XLON 17-Sep-2025 08:00:19 0XL064000000000088VUE9 3 1,462.50  XLON 17-Sep-2025 08:00:19 0XL064000000000088VUEH 9 1,461.50  XLON 17-Sep-2025 08:00:19 0XL061700000000088VUGH 12 1,462.00  XLON 17-Sep-2025 08:00:19 0XL061100000000088VUF2 12 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061400000000088VUGL 12 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061700000000088VUGO 12 1,462.50  XLON 17-Sep-2025 08:00:19 0XL06A000000000088VUJ5 13 1,462.00  XLON 17-Sep-2025 08:00:19 0XL06A000000000088VUIV 13 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061100000000088VUF6 13 1,462.50  XLON 17-Sep-2025 08:00:19 0XL067000000000088VUDF 13 1,462.50  XLON 17-Sep-2025 08:00:19 0XL06A000000000088VUJ6 14 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061700000000088VUGN 20 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061400000000088VUGP 206 1,462.50  XLON 17-Sep-2025 08:00:19 0XL061400000000088VUGO 7,635 1,461.50  XLON 17-Sep-2025 08:00:19 0XL061400000000088V